Please login to the form below
axicabtagene ciloleucel
This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
Latest news
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
The top-line results come from the phase 3 ZUMA-7 trial, which is investigating Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line LBCL.
-
Yescarta gains first FDA approval for indolent follicular lymphoma
Specifically, Yescarta (axicabtagene ciloleucel) has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) – a form of indolent non-Hodgkin lymphoma (iNHL) – after two or ... In the ZUMA-12 trial,
-
FDA approves BMS’ blood cancer CAR T therapy after delay
Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL, including DLBCL.
-
Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4
This includes Yescarta (axicabtagene ciloleucel) and Tecartus M (brexucabtagene autoleucel), which helped to grow sales by 34% to $163m in Q4 and 33% to $607m for the entire year.
More from news
Approximately 1 fully matching, plus 48 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
-
Deal Watch January 2017
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Moderna to launch Innovation and Technology Center in the UK
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022
- How digital health is changing the relationship between patients and health providers | OPEN Health
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Roche shares new positive Ocrevus data for MS patients
- Six UK universities receive grant for research into motor neurone disease
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
